Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amphastar Pharmaceuticals Inc (AMPH) vs Quantumscape Corp (QS) Price & Performance

Amphastar Pharmaceuticals IncTrade
Quantumscape CorpTrade

Price performance (Past 24H)

Key statistics

Amphastar Pharmaceuticals Inc vs Quantumscape Corp — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Quantumscape Corp trades at $6.5 (market cap $4.05B). The key difference: Quantumscape Corp is far larger — about 4.9× Amphastar Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.

AMPHQS
Market Cap
$826.08M$4.05B
Sector
HealthConsumer Cyclical
52-Week High
$30.81$18.44
52-Week Low
$16.87$5.96
Enterprise Value
$1.22B$3.21B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amphastar Pharmaceuticals Inc

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

Quantumscape Corp

QuantumScape (QS) trades at $6.58, down 4.78% today, with a bearish technical outlook and negative profitability metrics. The company reported a net loss of $435.05 million in 2025, though cash flow improved to a net positive $85.27 million. Recent news highlights a joint research agreement with Honda, providing optimism for solid-state battery development. Analyst consensus is cautious, with 73% hold ratings and no buy recommendations.

The outlook remains speculative due to high cash burn and unproven commercialization. Risks include execution delays and EV market volatility. Upside depends on successful battery deployment, but near-term financial pressure and bearish sentiment suggest cautious investor positioning.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amphastar Pharmaceuticals Inc

Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.

Read more on AMPH

About Quantumscape Corp

QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles. It developed anode-less cell design, which delivers high energy density while lowering material costs and simplifying manufacturing.

Read more on QS